{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Corry SM"],"funding":["Cancer Research UK","Medical Research Council","Public Health Agency","Wellcome Trust","Biotechnology and Biological Sciences Research Council"],"pagination":["2502-2517"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9664095"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["71(12)"],"pubmed_abstract":["<h4>Objective</h4>Stroma-rich tumours represent a poor prognostic subtype in stage II/III colon cancer (CC), with high relapse rates and limited response to standard adjuvant chemotherapy.<h4>Design</h4>To address the lack of efficacious therapeutic options for patients with stroma-rich CC, we stratified our human tumour cohorts according to stromal content, enabling identification of the biology underpinning relapse and potential therapeutic vulnerabilities specifically within stroma-rich tumours that could be exploited clinically. Following human tumour-based discovery and independent clinical validation, we use a series of <i>in vitro</i> and stroma-rich <i>in vivo</i> models to test and validate the therapeutic potential of elevating the biology associated with reduced relapse in human"],"journal":["Gut"],"pubmed_title":["Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer."],"pmcid":["PMC9664095"],"funding_grant_id":["MC_PC_17117","A31287","15333","A28223","24387","29834","EAT/4905/13","A17196","MR/M016587/1","A26825","MR/S021205/1","26045","206314/Z/17/Z","A21139","A29834","S_4137","BB/T002824/1","STL/5175/15","110371/Z/15/Z","G0400302"],"pubmed_authors":["Maguire S","Malla SB","White M","Amirkhah R","Lawler M","Coleman HG","McCooey AJ","Kerr EM","Maughan T","Tejpar S","Leonard NA","Leedham SJ","Tsantoulis P","Small DM","Sakhnevych S","S:CORT and ACRCelerate consortia","Cortes-Lavaud X","Loughrey MB","Jackstadt RF","Lannagan TR","Gillespie MA","McCorry AM","Corry SM","Fisher NC","Campbell AD","McDade SS","Byrne RM","Richman SD","Redmond KL","Sansom OJ","Ryan AE","Longley DB","Dunne PD","Rogan E"],"additional_accession":[]},"is_claimable":false,"name":"Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer.","description":"<h4>Objective</h4>Stroma-rich tumours represent a poor prognostic subtype in stage II/III colon cancer (CC), with high relapse rates and limited response to standard adjuvant chemotherapy.<h4>Design</h4>To address the lack of efficacious therapeutic options for patients with stroma-rich CC, we stratified our human tumour cohorts according to stromal content, enabling identification of the biology underpinning relapse and potential therapeutic vulnerabilities specifically within stroma-rich tumours that could be exploited clinically. Following human tumour-based discovery and independent clinical validation, we use a series of <i>in vitro</i> and stroma-rich <i>in vivo</i> models to test and validate the therapeutic potential of elevating the biology associated with reduced relapse in human","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2026-06-15T05:54:05.985Z","creation":"2024-11-12T17:37:03.615Z"},"accession":"S-EPMC9664095","cross_references":{"pubmed":["35477539"],"doi":["10.1136/gutjnl-2021-326183"]}}